Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.

Johnson CC, Kessel B, Riley TL, Ragard LR, Williams CR, Xu JL, Buys SS; Prostate, Lung, Colorectal and Ovarian Cancer Project Team.

Gynecol Oncol. 2008 Sep;110(3):383-9. doi: 10.1016/j.ygyno.2008.05.006. Epub 2008 Jun 30.

2.

Abnormal CA-125 levels in menopausal women without ovarian cancer.

Terada KY, Elia J, Kim R, Carney M, Ahn HJ.

Gynecol Oncol. 2014 Oct;135(1):34-7. doi: 10.1016/j.ygyno.2014.08.008. Epub 2014 Aug 13.

3.

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team.

JAMA. 2011 Jun 8;305(22):2295-303. doi: 10.1001/jama.2011.766.

PMID:
21642681
4.

Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.

Nyante SJ, Black A, Kreimer AR, Duggan MA, Carreon JD, Kessel B, Buys SS, Ragard LR, Johnson KA, Dunn BK, Lamerato L, Commins JM, Berg CD, Sherman ME.

Gynecol Oncol. 2011 Mar;120(3):474-9. doi: 10.1016/j.ygyno.2010.11.015. Epub 2010 Dec 7.

5.

Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.

Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, Hartge P, Fagerstrom RM, Ragard LR, Chia D, Izmirlian G, Fouad M, Johnson CC, Gohagan JK; PLCO Project Team.

Am J Obstet Gynecol. 2005 Nov;193(5):1630-9. Erratum in: Am J Obstet Gynecol. 2005 Dec;193(6):2183-4.

PMID:
16260202
6.
7.

Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.

Lotan Y, Karam JA, Shariat SF, Gupta A, Roupret M, Bensalah K, Margulis V.

Urol Oncol. 2016 Apr;34(4):167.e9-16. doi: 10.1016/j.urolonc.2015.10.011. Epub 2015 Nov 18.

PMID:
26602092
8.

Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.

Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K.

Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8. doi: 10.1158/1940-6207.CAPR-10-0402.

9.

Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, Gohagan J, Berg CD, Prorok PC.

Gynecol Oncol. 2016 Nov;143(2):270-275. doi: 10.1016/j.ygyno.2016.08.334. Epub 2016 Sep 9.

PMID:
27615399
10.

Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.

Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S, Kitanaka T, Oi H.

Gynecol Obstet Invest. 2008;65(2):133-8. Epub 2007 Oct 23.

PMID:
17957102
11.

Ovarian cancer screening in women with a family history of breast or ovarian cancer.

Lacey JV Jr, Greene MH, Buys SS, Reding D, Riley TL, Berg CD, Fagerstrom RM, Hartge P.

Obstet Gynecol. 2006 Nov;108(5):1176-84.

PMID:
17077240
12.

Factors influencing serum CA125II levels in healthy postmenopausal women.

Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):489-93.

13.

Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Pinsky PF, Ford M, Gamito E, Higgins D, Jenkins V, Lamerato L, Tenorio S, Marcus PM, Gohagan JK.

J Natl Med Assoc. 2008 Mar;100(3):291-8.

PMID:
18390022
14.

Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.

Menon U, Talaat A, Jeyarajah AR, Rosenthal AN, MacDonald ND, Skates SJ, Sibley K, Oram DH, Jacobs IJ.

Br J Cancer. 1999 Jul;80(10):1644-7.

15.

[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H.

Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6. Chinese.

PMID:
19134334
16.

Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.

Pinsky PF, Zhu C, Skates SJ, Black A, Partridge E, Buys SS, Berg CD.

Int J Cancer. 2013 May 1;132(9):2127-33. doi: 10.1002/ijc.27909. Epub 2012 Nov 5.

17.

Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.

Tailor A, Bourne TH, Campbell S, Okokon E, Dew T, Collins WP.

Ultrasound Obstet Gynecol. 2003 Apr;21(4):378-85.

18.

Tumor marker trends in asymptomatic women at risk for ovarian cancer: relevance for ovarian cancer screening.

Cane P, Azen C, Lopez E, Platt LD, Karlan BY.

Gynecol Oncol. 1995 May;57(2):240-5.

PMID:
7729742
19.

Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers.

MacDonald DJ, Sarna L, Uman GC, Grant M, Weitzel JN.

Oncol Nurs Forum. 2006 Nov 3;33(2):E27-35.

PMID:
16518435
20.

Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.

Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV, Takefman J, Grigorie MS, Artho G, Krishnamurthy S; DOvE Study Group.

Lancet Oncol. 2012 Mar;13(3):285-91. doi: 10.1016/S1470-2045(11)70333-3. Epub 2012 Jan 17.

PMID:
22257524

Supplemental Content

Support Center